Simultaneous assessment of DOACs effect on clot formation and fibrinolysis with the FibWave

Evrard, Jonathan; Maloteau, Vincent; Dogné, Jean‐Michel; Douxfils, Jonathan

doi:10.1111/ijlh.13723

Cited by 1 publication

(12 citation statements)

References 11 publications

(15 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In vitro results showed encouraging performances of this methodology and reveals its high sensitivity toward prothrombotic tendencies and anticoagulant status. 12 , 25 , 40 …”

Section: Discussionmentioning

confidence: 99%

“…The fibrinolysis pathway, that is, FibLysis, was assessed using a mixture of tissue factor, phospholipids, and tissue plasminogen activator at near physiological concentrations, as described previously. 12 The extracted parameters from the FibLysis were the maximum fibrinolysis velocity (|Min1| in dmAbs/dt 1 ), the fibrinolysis time (TFib in seconds) and the difference between time to lyse and time to clot (TFib‐Ttpeak in seconds) (Figure S1 ). Briefly, 100 μl of plasma samples were mixed with 25 μl of the corresponding reagent.…”

Section: Methodsmentioning

confidence: 99%

“… 3 , 4 , 5 , 6 As for the other direct oral anticoagulants (DOACs), edoxaban is also known to impact coagulation assays 3 , 7 , 8 , 9 and enhance factor X (FX)‐dependent fibrinolysis and plasmin generation. 10 , 11 , 12 …”

Section: Introductionmentioning

confidence: 99%

“…Compared to CWA, FibWave was developed to be more sensitive and to allow evaluation of the overall coagulation process by measuring the turbidity changes created during the clot formation process. 12 , 25 , 27 , 32 The suitability of FibWave for evaluating the impact of DOACs on clot formation and fibrinolysis and for the detection of hormone‐induced changes in coagulation proteins has already been reported. 12 , 25 , 32 These investigations were performed in normal pooled plasma supplemented with DOACs and not in patients treated with DOACs.…”

Section: Introductionmentioning

confidence: 99%

“… 12 , 25 , 27 , 32 The suitability of FibWave for evaluating the impact of DOACs on clot formation and fibrinolysis and for the detection of hormone‐induced changes in coagulation proteins has already been reported. 12 , 25 , 32 These investigations were performed in normal pooled plasma supplemented with DOACs and not in patients treated with DOACs.…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Comparison of analytical performances between clot waveform analysis and FibWave in edoxaban‐treated patients and healthy controls

Evrard

Siriez

Bouvy³

et al. 2022

Research and Practice in Thrombosis and Haemostasis

Self Cite

View full text Add to dashboard Cite

Introduction The activated partial thromboplastin time (aPTT) and the prothrombin time (PT) are widely available coagulation parameters which are however poor predictors of the anticoagulant effect of direct oral anticoagulants (DOACs). Some coagulometers use the clot waveform analysis (CWA) to assess the clotting time but mainly based on a unique parameter. The improvement of these methodologies and the evaluation of the other waveform parameters may increase the sensitivity to DOACs. Objectives To assess the performance of an improved clot waveform an method (i.e. FibWave) to detect the impact of edoxaban on the coagulation and the fibrinolytic systems. Methods Seventy‐one samples from patients treated with edoxaban collected at minimum concentration (C TROUGH ) and/or maximum concentration (C MAX ), and 45 control samples were included. The aPTT‐ and PT‐based CWA as well as the FibIn, FibEx, and FibLysis methodologies of the FibWave were implemented and performed on an ACL‐TOP 700. Results PT and FibEx clotting time were strongly correlated to edoxaban concentration (Pearson r = 0.80 and 0.89, respectively). The FibEx clotting time allowed a better discrimination for samples with 30 and 50 ng/ml of edoxaban compared to PT (cutoffs of 96.5 and 114.2 s for the FibEx versus a unique cutoff of 13.1 s for the PT). The fibrinolytic process was impaired in the presence of edoxaban in a dose‐dependent manner. Conclusion FibEx is more sensitive than aPTT‐ and PT‐based CWA for the detection of the clinically relevant anticoagulant level of edoxaban.

show abstract

“…In vitro results showed encouraging performances of this methodology and reveals its high sensitivity toward prothrombotic tendencies and anticoagulant status. 12 , 25 , 40 …”

Section: Discussionmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%